STAA STAAR Surgical Company
USHealthcareAs of 2026-07-10 16:00
Why STAA matters now
STAAR Surgical Company (STAA) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.76 with -0.75% on the session and $1.38B in market capitalization; recent performance reads 1-month -10.67% and YTD +26.12%.
The latest financial table shown here is Q1 2026, with revenue of $93.5M, net income of $5.2M, and EPS of $0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.
The latest indexable market news headline is "Hedge Fund Broadwood Capital Added Over 1 Million Shares of STAAR Surgical to Its Position. Here's What That Means for Investors." from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Hold with a median target of $31.50; recent insider activity includes Zhou Lilian Yansheng filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.12
P/S
4.99
EV/EBITDA
-330.07
DCF Value
$-0.35
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.4%
Operating Margin
-1.7%
Net Margin
-7.2%
ROE
-6.1%
ROA
-4.7%
ROIC
-1.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $93.5M | $5.2M | $0.10 |
| Q4 2025 | $57.8M | $-18.3M | $-0.36 |
| FY 2025 | $239.4M | $-80.4M | $-1.62 |
| Q3 2025 | $94.7M | $8.9M | $0.18 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$29.33
Target (Median)
$31.50
Target Range
$13.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.23
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.